Comparative Pharmacology
Head-to-head clinical analysis: ACTIVASE versus RETAVASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIVASE versus RETAVASE.
ACTIVASE vs RETAVASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tissue plasminogen activator that converts plasminogen to plasmin, degrading fibrin clots.
Reteplase is a recombinant non-glycosylated form of tissue plasminogen activator that binds to fibrin and converts plasminogen to plasmin, leading to fibrinolysis.
Acute ischemic stroke: 0.9 mg/kg IV (max 90 mg) infused over 60 minutes, with 10% of total dose given as IV bolus over 1 minute. Acute myocardial infarction: Total dose of 100 mg administered IV as a 15 mg bolus, then 50 mg infused over 30 minutes, then 35 mg infused over 60 minutes. Pulmonary embolism: 100 mg IV infused over 2 hours.
10 IU (two 5 IU vials) administered as two separate IV bolus injections, each over 2 minutes, given 30 minutes apart.
None Documented
None Documented
4-6 minutes initially (alpha phase), then terminal half-life of 20-40 minutes for fibrin-bound alteplase; clinical context: requires continuous infusion.
Mean terminal elimination half-life: 3.0–4.5 hours (range 1.5–6.0 hours). Clinical context: The short half-life reduces bleeding risk compared to longer-acting thrombolytics; re-administration may be needed for sustained effect.
Primarily hepatic clearance; renal excretion negligible, <1% unchanged in urine. Fecal elimination unknown as endogenous enzyme.
Primarily hepatic metabolism; no significant renal or biliary excretion of active drug. Elimination is via proteolytic degradation with subsequent renal excretion of inactive metabolites.
Category C
Category C
Thrombolytic Agent
Thrombolytic Agent